MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Gl...( REHOVOT Israel and JERSEY CITY Ne...),Health

REHOVOT, Israel and JERSEY CITY, New Jersey, September 18 /PRNewswire-FirstCall/ -- - A Collaborative Study by Scientists at the Weizmann Institute of Science and Scientists at Sheba Medical Center, With the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451 Inhibited Growth of Glioblastoma (GBM) Cells

- Furthermore, Combining Imatinib (Gleevec(R)), a Targeted Cancer Drug Approved Treatment of Chronic Myelogenous Leukemia (CML) and Gastrointestinal Stromal Tumors Manufactured by Novartis, With miR-451 had a Synergistic Effect in Inhibiting GBM Growth

- miR-451 was First Disclosed in a Patent Application by Rosetta Genomics and is Currently Under Active Examination

Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that a collaborative study published by scientists from the Weizmann Institute of Science and scientists at Sheba Medical Center, with the aid of Rosetta Genomics, has demonstrated that a microRNA first disclosed by the company increased the efficacy of Imatinib (Gleevec(R)) in Glioblastoma (GBM), the most common and most aggressive type of primary brain tumor.

"We are excited to be part of this important study led by the renowned scientists from the Weizmann Institute of Science and from the Sheba Medical Center," noted Dr. Dalia Cohen, Chief Scientific Officer at Rosetta Genomics. "MicroRNAs are quickly emerging as major regulators of biological processes and have wide diagnostic and therapeutic potential. Rosetta Genomics' extensive intellectual property portfolio which includes the first ever issued patent relating to microRNAs, as well as patent applications for a large portion of today's known microRNAs, positions us to lead the microRNA space and advance patient care worldwide. Our first microRNA-based products, diagnosing various cancers, are expected to be launched later this year."

In the study, "MIR-451 and Imatinib Mesylate Inhibit the Growth of Glioblastoma Stem Cells", published on
'/>"/>